GLP-1 Users Report Higher Rates of Hair, Nail Issues
A 2026 study finds links between GLP-1 medications and increased occurrences of various dermatological symptoms.
Updated on Oct. 21, 2026 in Diabetes
Live Poll
Would you reconsider using weight-loss drugs if they were linked to hair and nail issues?
Researchers have identified an association between the use of GLP-1 receptor agonists and increased reports of specific hair and nail conditions. The findings, presented at the 2026 European Academy of Dermatology and Venereology Congress, highlight dermatological trends among medication users compared to nonusers.
Why it matters
The study provides evidence of potential side effects beyond typical metabolic outcomes associated with GLP-1 drugs. Understanding these dermatological risks is essential for patients and providers monitoring health changes during treatment.
In a study of 575 GLP-1 users and 1,329 controls, 66% of medication users reported at least one nail disorder compared to 53% of nonusers. Furthermore, nail discoloration affected 46% of GLP-1 users versus 17% of controls.
The players
European Academy of Dermatology and Venereology
This professional organization is dedicated to promoting excellence in clinical care, research, and education in the field of dermatology and venereology.
The details
The cross-sectional study recruited participants from France, the United States, Brazil, and Mexico to track symptoms like scalp redness and reduced hair volume. Researchers accounted for existing dermatological conditions and nutritional deficiencies, though roughly half of the medication users reported nail problems before beginning their treatment.
Timeline
The European Academy of Dermatology and Venereology Congress occurred in 2026.
The Big Picture
This study extends the body of clinical evidence presented at the European Academy of Dermatology and Venereology Congress regarding dermatological reactions to systemic treatments. It signals a shift toward identifying a wider range of patient-reported symptoms in long-term medication use.
Patients using GLP-1 medications should monitor for changes in hair volume or nail integrity and report these symptoms to their healthcare provider. Future prospective studies are expected to provide clearer biological monitoring and diagnostic standards for these potential side effects.
The takeaway
Patients experiencing new dermatological concerns while on GLP-1 therapy should maintain a record of symptom onset to discuss during medical checkups. Awareness of these findings helps ensure that hair and nail health is properly addressed alongside primary metabolic treatment goals.
Further reading
For more context on how treatments impact patient health, visit the Diabetes section.
Source note: This article includes information reported by Labroots.
Live Poll
Would you reconsider using weight-loss drugs if they were linked to hair and nail issues?
